Immunology
TxCell, a biotechnology company developing personalised cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, will participate at the second French Life Sciences Days in New York, US, on 17–18 June 2015. The investor’s conference will be held at W Hotel, 541 Lexington Avenue, New York on Thursday, June 18.
This event is organised by France Biotech. TxCell also participated at the inaugural French Life Sciences Days in 2014, which attracted more than 50 American investors and the organisation of 70 face-to-face meetings. This event aims to bring together French life sciences companies listed on stock market with the North American financial community. During the 2015 Life Science Days, TxCell and 17 other French biotechnology and medical technology companies listed on the French stock market will present and hold face-to-face meetings with specialised North American investments funds, banks, financial analysts and media.
Stephane Boissel, CEO, TxCell will present an update on TxCell’s ASTrIA technology platform and its personalised cellular immunotherapy programmes for the treatment of several severe chronic inflammatory and autoimmune diseases.
“The body of scientific evidence that T regulatory cells could play as big role in autoimmunity and chronic inflammation as T effector cells in oncology is continuing to grow. This is one key reason for the level of interest that TxCell is generating amongst those attending this and other events,” said Stephane Boissel, CEO TxCell. “This interest provides additional encouragement for us both individually and with partners to accelerate the development of TxCell’s platforms and product portfolio.”